
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics is facing risks in regards to clinical, regulatory, and financial matters, as unpredicted issues may arise. However, the company may see potential upside from strategic alternative plans that could add value or unexpected regulatory flexibility. Despite discontinuing the development of pociredir for SCD due to concerns of potential secondary hematologic malignancies, Fulcrum plans to review strategic alternatives and reduce operating expenses to preserve capital and extend cash runway. As of 1Q:26, Fulcrum had $333.3 million in cash.
Bears say
Fulcrum Therapeutics is facing challenges in its development of pociredir for sickle cell disease, causing the company to discontinue the program and undergo a strategic review and restructuring. This unexpected setback, combined with the potential for future clinical and regulatory risks, lead to a negative outlook for the company and a recommendation to hold the stock. Additionally, the company may require additional capital to continue its operations.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares